Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2016-02-23 AGM Information
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
AGM Information 2016
AGM Information Classification · 99% confidence The document explicitly states it is a 'Company Announcement' summoning the 'Annual General Meeting on March 17, 2016' and details the full 'Agenda' for this meeting. The agenda items cover the Annual Report adoption (Item 2), election of directors (Item 4), auditor election (Item 5), and several proposals regarding remuneration, share repurchase authorization, and amendments to the Articles of Association (Item 6). This content is characteristic of the official notice and materials distributed to shareholders in preparation for an AGM, which aligns perfectly with the definition of AGM Information (AGM-R). It is not the full 10-K, nor is it just an Earnings Release (ER) or a general proxy statement (PSI), as it is specifically focused on the meeting logistics and proposals.
2016-02-23 English
Indkaldelse til ordinær generalforsamling i Genmab A/S
Proxy Solicitation & Information Statement Classification · 90% confidence The document is a detailed notice summoning shareholders to Genmab A/S’s Annual General Meeting, including the full agenda with resolutions, complete proposals, and background on board elections and amendments to the Articles of Association. It is not the minutes or presentations from the meeting, nor is it merely an announcement that a report is available. Instead, it provides the information required by shareholders to consider and vote on the proposals at the AGM, which aligns with our definition of a Proxy Solicitation & Information Statement (PSI).
2016-02-23 English
Indkaldelse til ordinær generalforsamling i Genmab A/S
Proxy Solicitation & Information Statement Classification · 100% confidence The document is an official 'Indkaldelse til ordinær generalforsamling' (Notice of Annual General Meeting) for Genmab A/S. It contains the agenda, proposals for board elections, remuneration policies, and amendments to the articles of association. This document is a formal solicitation of shareholder participation and voting for an upcoming meeting, which falls under the category of Proxy Solicitation & Information Statement.
2016-02-23 English
Earnings Release 2015
Earnings Release Classification · 95% confidence The document explicitly states: "Company Announcement... Genmab A/S (OMX: GEN) announced today its Annual Report for 2015. Below is a summary of business progress and financial performance for the year... The full report is attached as a PDF file and can be found on the investor section of the company’s website...". This structure—an announcement summarizing key highlights (2015 Achievements, Financial Performance, 2016 Outlook) and directing the reader to the full, attached Annual Report—fits the definition of an Earnings Release (ER) or, more specifically, a Report Publication Announcement (RPA) if the primary purpose is just to announce the availability of the full report. However, since the text contains substantial financial summaries (Revenue, Operating Expenses, Operating Income, Cash Position) and business progress updates, it functions as the primary release of the period's results, which aligns closely with an Earnings Release (ER). Given the context that the full 10-K/Annual Report is separate and attached, this summary document is best classified as an Earnings Release (ER) which precedes the filing of the full 10-K. If the document were purely a short notice saying 'The 10-K is available,' it would be RPA. Since it contains the core financial summary, ER is the most appropriate fit among the options provided for a periodic results announcement. FY 2015
2016-02-17 English
Annual Report 2015
Annual Report Classification · 100% confidence The document is explicitly titled 'ANNUAL REPORT 2015' and contains comprehensive sections including a Directors' Report, Financial Statements, Auditor's Report, and detailed business performance analysis. It is a full-length annual report for Genmab A/S, not an announcement or a summary. FY 2015
2016-02-17 English
Major Shareholding Notification 2016
Major Shareholding Notification Classification · 98% confidence The document is titled "Company Announcement" and explicitly states it is a "Major shareholder announcement for Genmab A/S". The core content details that Johnson & Johnson Innovation – JJDC, Inc. has informed Genmab that its ownership has fallen below the 5% threshold regarding voting rights and share capital, referencing the Danish Securities Trading Act. This type of filing, which reports changes in significant share ownership crossing a specific threshold (5% in this case), directly corresponds to the definition of Major Shareholding Notification (MRQ). The document length is short (3774 chars), but the content is a specific regulatory disclosure, not just an announcement of another report, making MRQ the most precise fit over the general fallback RNS.
2016-02-04 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.